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Background: Almost half of head and neck (H&N) cancer patients is 65 years or older, 
however the use of comprehensive geriatric assessment (CGA) to quantify functional age in 
these patients has not been studied. Moreover, the search for an optimal screening tool to 
identify patients in need of a full CGA is still ongoing. We examined (1) a disease-specific 
Combined Screening Tool (CST, “VES-13+(17-G8)”), (2) the feasibility of serial CGA, and 
(3) its ability to indicate Quality of Life (QoL). 
Methods: Patients, aged ≥65y, with primary H&N cancer undergoing curative 
radio(chemo)therapy were evaluated with VES-13, G8, CGA, and EORTC QoL 
Questionnaire at baseline (W0) and during week 4 (W4) of their therapy at the General 
Hospital Groeninge or Ghent University Hospital. Receiver Operating Characteristic analysis 
was used to determine the diagnostic accuracy of the CST. Wilcoxon signed rank test and Mc 
Nemar’s Exact test were performed for comparison of health status at both time points. 
Repeated measures ANOVA were applied to examine potential differences in EORTC QoL 
data between fit and vulnerable patients (as defined by baseline CGA). 
Results:  One hundred primarily male (86.0%) patients, with a median age of 72 (range 65-
86), and mostly presenting with an advanced-stage cancer (69.0%, stage III-IVb) of the larynx 
(45.0%), pharynx (34.0%), oral cavity (15.0%), or involved neck nodes of an occult primary 
(6.0%) were recruited. At W0, 71.3%, 36.8%, 69.0%, and 61.2% were defined vulnerable 
according to CGA (cut-off ≥2 positive domains), VES-13 (cut-off ≥3), G8 (cut-off ≤14) and 
CST (cut-off ≥5) respectively. The proportion ((Sensitivity+Specificity)/2) of the CST 
(79.5%) did not significantly differ from the clinically relevant proportion of 75.0% necessary 
for validation. At W0, patients experienced mostly severe grade co-morbidities (74.7%), 
difficulties in community functioning (50.6%) and nutritional problems (50.6%). Significantly 
more patients were considered vulnerable at W4 by CGA (83.9%, p<0.01), VES-13 (57.5%, 
p<0.0001), and G8 (92.0%, p<0.0001), deteriorating especially at the nutritional (p<0.0001), 
functional (p<0.0001) and emotional (p<0.01) level. Vulnerable patients generally reported 
lower QLQ functioning and higher symptom scores at both time-points, compared to fit 
patients. A comparable deterioration in QoL was observed in both groups through therapy.  
Conclusions: We were unable to validate the CST according to the predefined hypothesis. 
The G8 screening tool therefore presently remains standard of care to identify patients in need 
of a full CGA. Our data suggest that CGA classification is indicative of QoL. Moreover, it 
identifies the multidimensional health problems and their evolution during radiotherapy, 
guiding individualized supportive care. It should therefore be integrated in the treatment 
approach and follow-up of elderly H&N cancer patients.  
 
